Tirzepatide and exercise training in obesity.

What Was Tested

Researchers studied Tirzepatide in this randomized controlled trial publication.

The purpose of this study was to investigate the effects of 6 weeks of resistance training (RT) combined with aerobic training (AT) and Tirzepatide supplementation on lipid profiles, insulin resistance, anthropometric characteristics and physical fitness in prediabetic obese soldiers.

Who Took Part

The abstract describes 61 men taking part.

By PubMed's age tags, the people studied were adults, men only.

Before and after the intervention period, the participants were evaluated for anthropometric measures, body composition [body weight, body mass index (BMI), waist circumference (WC), waist to hip ratio (WHR) and fat mass (FM)], cardiorespiratory fitness (VO2max), and muscle strength (chest press 1RM and leg press 1RM).

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The men were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

All training groups performed aerobic training (AT) after resistance training.

Blood biochemistry evaluations included triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), insulin level and insulin resistance (HOMA-IR).

What Was Measured

PubMed files the paper under topics including Obesity, Insulin Resistance, Resistance Training, Exercise and Body Mass Index.

The authors tagged it with the keywords GIP, GLP-1, Tirzepatide and combined training.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Tirzepatide in 61 men.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Clinical hemorheology and microcirculation), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.